OVERVIEW

Update on Parkinson’s Disease and Alzheimer’s Disease Treatments is organized by Pri-Med. This Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits™.

Effective Date: 12/11/2018.
Expiration Date: 12/11/2021.

Topics: Neurology

Course Description:
Alzheimer’s disease and Parkinson’s disease are the two most common neurodegenerative disorders, affecting over 6 million people in the U.S. Like nearly all of this class of disorders, these two conditions are due to the misfolding and accumulation of proteins in the central nervous system. This new way of viewing these conditions, as protein misfolding disorders, will be presented. We will review amyloid, tau and alpha-synuclein, the proteins that build up respectively in plaques, tangles and lewy bodies. We’ll review currently available therapies and the therapies that are being developed to more directly attack these disorders and hopefully modify the course of the disease.

Learning Objectives:
• Review the epidemiology of Alzheimer’s disease and Parkinson’s disease, understanding the rapid increase in prevalence
• Place these disorders into context as "protein mis-folding" conditions and understand the implications of this framework
• Review currently available therapies for AD and PD
• Detail newer therapies aimed at modifying the course of the disease

Additional details will be posted as soon as they are available.